Results 21 to 30 of about 178 (87)

Integrative molecular simulations reveal NeuroAid II mechanisms in ischemic stroke through network pharmacology, molecular dynamics, and pharmacophore modeling [PDF]

Scientific Reports
Ischemic stroke remains a major health challenge with limited treatment options. NeuroAid II (MLC901), a multi-herbal remedy, has shown clinical promise in post-stroke recovery, though its molecular mechanisms are unclear.
Doni Dermawan, Stefeny Theresia Simatupang, Nadia Nadia, Santi Tan, Raymond Rubianto Tjandrawinata   +4 more
doaj   +2 more sources

Mechanical scratch injury on differentiated motor neuron of NSC-34 cells as an in vitro model for evaluation of neuroregeneration potential of NeuroAiD II (MLC901) [PDF]

In Vitro Models
Yogeswaran Lokanathan
exaly   +3 more sources

Endothelial cell-derived extracellular vesicles induce pro-angiogenic responses in mesenchymal stem cells. [PDF]

FEBS Open Bio
Human umbilical vein endothelial cell line‐derived small extracellular vesicles (EVs; <200 nm) (HU‐sEVs) were used as a pro‐angiogenic agent. They were characterized by evaluating morphology, size, and count. Chemical properties of HU‐sEVs were also investigated by antibody‐based and omics. All were based on MISEV criteria.
Abdik H, Kırbaş OK, Bozkurt BT, Avşar Abdik E, Hayal TB, Şahin F, Taşlı PN.   +6 more
europepmc   +2 more sources

A comprehensive review on adaptive plasticity and recovery mechanisms post-acquired brain injury. [PDF]

Neuroprotection
This figure illustrates the dynamic process of neurogenesis following brain injury, focusing on the roles of neural stem and progenitor cells at the injury site. Key mechanisms include axonal sprouting, synaptogenesis, dendritic remodeling, and brain‐derived neurotrophic factor signaling via TrkB receptors.
Rajan RK.
europepmc   +2 more sources

Cost-effectiveness of MLC601 in post-stroke functional recovery compared with placebo - the CHIMES & CHIMES-E studies [PDF]

BMC Health Services Research
Background Despite progress in stroke therapy (e.g., revascularisation interventions by thrombolysis and/or thrombectomy, organised stroke care), many stroke survivors will have impairment of neurological function.
Christopher Li Hsian Chen, Jia Hui Chai, Yogesh Mahadev Pokharkar, Narayanaswamy Venketasubramanian   +3 more
doaj   +2 more sources

NeuroAid™-II (MLC901) provides neuroprotection and enhances neuronal cell survival against kainic acid-induced excitotoxicity in vitro by activating the PI3K/AKT pathway

Future Journal of Pharmaceutical Sciences
In the twenty-first century, in vitro models of excitotoxic injury, leveraging advanced cellular and molecular technologies, offer a promising alternative to animal studies. These models provide a more precise understanding of injury mechanisms.
Anam Anjum, Muhammad Dain Yazid, Muhammad Fauzi Daud, Jalilah Idris, Angela Min Hwei Ng, Amaramalar Selvi Naicker, Ohnmar Htwe Ismail, Ramesh Kumar Athi Kumar, Yogeswaran Lokanathan   +8 more
doaj   +2 more sources

The role of MLC901 in reducing VEGF as a vascular permeability marker in rats with spinal cord injury. [PDF]

Ann Med Surg (Lond), 2022
Damaged neural tissue caused by SCI could induce vascular endothelial growth factor (VEGF) that can worsen the condition in the late phase by increasing vascular permeability, thus inducing tissue oedema, which can worsen the infarction. MLC 901 has been widely used in Asia for stroke patients because its mechanism is known to down-regulate VEGF levels
Wahyudi, Islam AA, Hatta M, Adhimarta W, Faris M, Mustamir N, Bukhari A, Prihantono, Kaelan C, Hendarto J, Imran NH, Rosyidi RM.   +11 more
europepmc   +4 more sources

Use of MLC901 in cerebral venous sinus thrombosis: Three case reports. [PDF]

World J Clin Cases
BACKGROUND Cerebral venous sinus thrombosis (CVT) is rare cause of cerebrovascular disease. The incidence is 0.5% of all stroke. The majority of affected patients are young adults (mean age: 35-40 years) with mild to moderate disabilities. Poor outcome with severe disability is seen in 13% of cases. Early diagnosis and treatment are important
Arsovska AA, Venketasubramanian N.
europepmc   +3 more sources

The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES) [PDF]

Cerebrovascular Diseases, 2013
<b><i>Background:</i></b> A substantial proportion of patients after nondisabling stroke are cognitively impaired compared to age- and education-matched community-dwelling controls. Moreover, poststroke patients who have ‘vascular cognitive impairment no dementia' (VCIND) of moderate severity have a high risk of incident ...
Chen, Christopher L.H., Ikram, Kamran, Anqi, Qiu, Yin, Wong Tien, Venketasubramanian, Narayanaswamy, Chen, Annabel Shen-Hsing   +5 more
openaire   +4 more sources

MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice [PDF]

Cerebrovascular Diseases, 2016
<b><i>Background:</i></b> There is increasing evidence that angiogenesis, through new blood vessel formation, results in improved collateral circulation and may impact the long-term recovery of patients. In this study, we first investigated the preventive action of a 5-week pretreatment of MLC901, an herbal extract preparation ...
Carine, Gandin, Catherine, Widmann, Michel, Lazdunski, Catherine, Heurteaux   +3 more
openaire   +2 more sources